Acadia Pharmaceuticals (ACAD) said late Tuesday it has struck a deal to sell its rare pediatric disease priority review voucher for $150 million.
Acadia said it was granted the voucher in March 2023 following approval from the US Food and Drug Administration of DAYBUE to treat Rett syndrome.
Acadia initially licensed DAYBUE from Neuren Pharmaceuticals in August 2018, and is required to pay Neuren a third of the net proceeds.
The company said it plans to invest the proceeds in commercial operations, research and development programs in the central nervous system and rare diseases, and in future business development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.